Lv42
540 积分 2024-02-03 加入
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study
4天前
已完结
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
9天前
已完结
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study
13天前
已完结
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
13天前
已完结
Strategies to optimize duration of immunotherapy in advanced NSCLC: Current evidence and future directions
13天前
已完结
Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the I-STOP study
13天前
已完结
The immune response to major gastrointestinal cancer surgery and potential implications for adjuvant immunotherapy
14天前
已完结
Neoadjuvant checkpoint blockade for cancer immunotherapy
16天前
已完结
First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial
16天前
已完结
Longitudinal circulating tumor DNA monitoring in predicting response to short-course radiotherapy followed by neoadjuvant chemotherapy and camrelizumab in locally advanced rectal cancer: data from a Phase Ⅲ clinical trial (UNION)
18天前
已完结
皖公网安备34019202002308
